PRJNA275480
Hepatitis C virus subtype 1b Targeted Locus (Loci)
Daclatasvir and asunaprevir dual oral therapy is expected to achieve high sustained virological response rates in patients with HCV genotype 1b infection. However, presence of the NS5A-Y93H substitution at baseline has been shown to be an independent predictor of treatment failure for this regimen. To develop a probe-based rapid evaluation system for the drug resistant variant strain frequency, using a total of 55 sera from HCV genotype 1b-infected Japanese patients, we performed ultra-deep sequencing and compared the proportion of the variant strain with those by the probe-based method.